Sanofi Q3 2025 Results: 7 % Revenue Growth, Dupixent Drives Pharma Upswing
Sanofi (NASDAQ: SNY) today reported its third‑quarter 2025 financial performance, posting a 7 % year‑on‑year increase...
Company
Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans
Shanghai CirCode Biomed Co. Ltd. today announced that its proprietary circular‑RNA (circRNA) therapeutic HM2003 Injection...
Huadong’s Mefatinib Approved by NMPA for EGFR‑Driven NSCLC
Huadong Medicine (SHE: 000963) announced that its Class 1 innovative drug Mefatinib Tablets has received marketing...
Hengrui Launches Henagliflozin Triple‑Combination Metformin for Type 2 Diabetes
Hengrui Medicine (SHA: 600276, HKG: 1276) today announced the commercial launch of its first independently developed...
CSPC’s SYH2061 Injection Receives NMPA Clinical‑Trial Approval for IgA Nephropathy
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its independently developed Class 1 chemical novel drug...
Boehringer Ingelheim’s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim announced that its oral selective phosphodiesterase‑4B (PDE4B) inhibitor Nerandomilast (JASCAYD®) has received formal...
Fosun Pharma & Helsinn Partner to Produce Fosnetupitant for Akynzeo in China
Fosun Pharma (SHA: 600196, HKG: 2196) and the Helsinn Healthcare SA announced a strategic cooperation...
PADCEV Yields 60 % EFS Reduction in MIBC – Astellas‑Pfizer EV‑303 Study
Astellas (TSE: 4503) and Pfizer (NYSE: PFE) announced that their pivotal Phase III EV‑303 (KEYNOTE‑905) trial...
AbbVie’s SELECT‑SWITCH Study Confirms Upadacitinib Outperforms Adalimumab in RA
AbbVie (NYSE: ABBV) announced positive topline data from its Phase IIIb/IV head‑to‑head trial, SELECT‑SWITCH, comparing upadacitinib...
Harbour BioMed Reports Phase II Success of Porustobart in MSS mCRC
China‑based Harbour BioMed (HKG: 2142) announced positive results from its multicenter, open‑label Phase II trial (NCT 05167071)...
Roche Reports 7 % YoY Revenue Growth Through Q3 2025, Raises Full‑Year Guidance
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its global group revenues grew 7 % year‑on‑year (YoY)...
Novo Nordisk Board Shake‑Up: Chairman Helge Lund and Six Members Step Down After Disagreement With Foundation
Novo Nordisk A/S (NYSE: NVO) announced today that Chairman Helge Lund and six other board...
Innovent and Takeda Forge $11.4 B Partnership on IBI363, IBI343 & IBI3001 ADC Therapies
Innovent Biologics, Inc. (HKG: 1801) today announced a landmark global strategic collaboration with Takeda Pharmaceutical...
Galapagos Announces Exit from Cell‑Therapy Business After Strategic Review
Galapagos NV (FRA: GXE) today disclosed that it has decided to wind down its cell‑therapy...
GFH375 Enters Phase Ib/II at Peking University: GenFleet Targets KRAS G12D
GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) today announced that the first patient has been enrolled...
Rani Therapeutics and Chugai Forge $1.085 Billion Collaboration Deal for Innovative Oral Therapeutic
Rani Therapeutics Holdings, Inc. today announced a comprehensive Collaboration and License Agreement with Japan’s Chugai...
BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4/6 IN BRIGHT‑3: Xuanzhu Biopharma Announces Interim Phase III Results at ESMO 2025
Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase III BRIGHT‑3...
Sichuan Biokin Secures NMPA Approval for BL‑M24D1 ADC, Targeting Relapsed Hematologic and Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the National Medical Products Administration (NMPA)...
Huadong Medicine Secures FDA Approval for DR10624, First‑In‑Class Trispecific Agonist for Severe Hypertriglyceridemia
Huadong Medicine (SHE: 000963) announced that the Investigational New Drug (IND) application for DR10624 Injection,...
AstraZeneca & Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY‑Breast11 at ESMO 2025
AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) disclosed the Phase III DESTINY‑Breast11 results at...